News Release

Printer Friendly VersionView printer-friendly version << Back



AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences

REDWOOD CITY, Calif., Feb. 21, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences, one in New York City, NY and one in Boston, MA, over the coming weeks as follows:

Citi 2012 Global Health Care Conference
Date:  Tuesday, February 28th at 10:30 AM EST
Location:  Waldorf Astoria Hotel in New York, NY
Webcast link:  http://www.veracast.com/webcasts/citigroup/healthcare2012/07206633.cfm

Cowen and Company 32nd Annual Health Care Conference
Date:  Tuesday, March 6th at 9:20 AM EST
Location:  The Boston Marriott Copley Place in Boston, MA
Webcast link:  http://wsw.com/webcast/cowen6/acrx/

Both presentations will be webcast live and can be accessed through the links above.  For those not available to listen to the live broadcast, the presentations will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the first quarter of 2012 under a grant from the US Army Medical Research and Material Command, or USAMRMC.

SOURCE AcelRx Pharmaceuticals, Inc.

Jim Welch, Chief Financial Officer of AcelRx Pharmaceuticals, Inc., +1-650-216-3511, jwelch@acelrx.com